TOMM22 and familial pancreatic carcinoma: Recently, one study revealed that TOMM22 overexpression promotes aggressive cell growth in in pancreatic cancer by modulating mitochondrial protein import and function, suggesting its potential as an early diagnostic/prognostic biomarker [35].